Low Dose Versus Standard Dose Albumin

Introduction Liver cirrhosis represents the terminal stage of chronic liver injury, characterized by fibrosis, distortion of hepatic architecture, and formation of regenerative nodules. It remains a major global health burden with significant mortality, particularly after the onset of decompensation.

Ascites develops as a consequence of portal hypertension and systemic circulatory alterations. It indicates advanced disease, especially when it becomes refractory to standard therapy. Refractory ascites is associated with reduced survival and often necessitates interventional management.

Large-volume paracentesis (LVP) is an established and commonly used therapeutic procedure for the management of tense or refractory ascites. It offers rapid symptomatic relief and is considered more effective and safer compared to alternative approaches such as transjugular intrahepatic portosystemic shunt in many clinical settings.

The procedure is particularly indicated in patients with tense ascites causing discomfort or respiratory compromise, as well as in those who fail to respond adequately to sodium restriction and diuretic therapy.

LVP is associated with a significant complication known as paracentesis-induced circulatory dysfunction (PICD). This condition typically occurs after removal of large volumes of ascitic fluid, especially more than 5-6 liters.

Paracentesis-induced circulatory dysfunction (PICD) is a condition marked by significant activation of the renin-angiotensin system, occurring as a result of worsening arteriolar vasodilation that is already present in cirrhotic patients. It can develop in up to 80% of patients who do not receive plasma expanders following large-volume paracentesis; however, the use of plasma volume expansion markedly decreases its incidence.

To prevent PICD, plasma volume expanders are routinely administered following LVP.Various expanders such as dextran, polygeline, and saline have been used; however, their efficacy in preventing PICD is variable. Among these, human albumin has emerged as the most widely used and effective agent.

Albumin is a key plasma protein synthesized by the liver, contributing significantly to oncotic pressure. In addition to its volume-expanding properties, albumin exhibits anti-inflammatory, antioxidant, and immunomodulatory effects, which may influence outcomes in patients with cirrhosis.

Hypoalbuminemia is common in cirrhotic patients due to decreased synthesis, dilution, and loss into ascitic fluid, further supporting the rationale for exogenous albumin administration.

The role of albumin in preventing PICD is well established. It acts by expanding plasma volume, improving circulatory function, and reducing activation of vasoconstrictor systems. Clinical studies have demonstrated that albumin significantly lowers the incidence of PICD and related complications, including renal dysfunction and hyponatremia, when compared with other plasma expanders.

However, the use of albumin is limited by its relatively high cost, particularly in resource-constrained settings. This has prompted investigation into lower dosing regimens that may provide similar efficacy while reducing financial burden. Conventional dosing recommendations often suggest 6-8 g of albumin per liter of ascitic fluid removed, but emerging evidence indicates that reduced doses, such as 4 g/L, may be effective and more economical.

In addition to circulatory dysfunction, patients undergoing large-volume paracentesis remain at risk of subsequent renal impairment, worsening liver function. These clinically relevant outcomes contribute to morbidity, repeated hospital visits, and poorer prognosis in patients with decompensated cirrhosis.

Given the clinical importance of preventing PICD and the economic implications of albumin therapy, there is a need to evaluate whether lower doses of albumin are as effective as standard doses. This study aims to compare reduced-dose albumin (4 g/L) with standard-dose albumin (6g/L) in preventing PICD following large-volume paracentesis, with the goal of optimizing both clinical outcomes and cost-effectiveness.

General Objective

To evaluate the effectiveness of low-dose albumin (4 g/L) compared to standard-dose albumin (6g/L) in preventing paracentesis-induced circulatory dysfunction (PICD) in patients with liver cirrhosis undergoing large-volume paracentesis.

Specific Objectives

1. To compare renal function (serum creatinine) before and following large-volume paracentesis in both groups.
2. To evaluate the occurrence of hyponatremia after paracentesis in patients receiving low-dose versus standard-dose albumin.
3. To compare Plasma Renin Activity (PRA) in patients receiving low-dose versus standard-dose albumin.
4. To compare the adverse effects in patients receiving low-dose versus standard-dose albumin.
5. To compare the incidence of paracentesis-induced circulatory dysfunction between low-dose and standard-dose albumin groups